Dicerna Pharmaceuticals
Jul 11, 2014

Dicerna to Ring the NASDAQ Stock Market Closing Bell July 15th

WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced that the Company will ring the NASDAQ Stock Market closing bell on Tuesday, July 15, 2014.

"Dicerna has achieved significant milestones in the first half of 2014 including completing a very successful initial public offering in January and initiating our first in-human Phase 1 clinical trial of DCR-MYC, our dicer substrate RNA interference candidate (DsiRNA), in patients with solid tumors, multiple myeloma, or lymphoma," said Douglas Fambrough, PhD, Chief Executive Officer of Dicerna. "Ringing the closing bell at NASDAQ is a symbolic way for the company to recognize the great strides it has made this year."

Dr. Fambrough and the Dicerna management team will ring the closing bell on July 15 from 3:45 p.m. to 4:00 p.m. ET. A live webcast will be available at: https://new.livestream.com/nasdaq/live.

About Dicerna Pharmaceuticals, Inc.

Dicerna is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare, inherited diseases involving the liver and for cancers that are genetically defined. The Company is using its proprietary RNA interference (RNAi) technology platform to build a broad pipeline in these therapeutic areas. In both rare diseases and oncology, Dicerna is pursuing targets that have historically been difficult to inhibit using conventional approaches, but where connections between targets and diseases are well understood and documented. The Company intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. For more information, please visit www.dicerna.com.

Cautionary Contact on Forward-looking Statements

This press release includes forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those relating to our preclinical research and other risks identified under the heading "Risk Factors" included in our Form 10-Q dated May 14, 2014, and in other future filings with the SEC. The forward-looking statements contained in this press release reflect Dicerna's current views with respect to future events, and Dicerna does not undertake and specifically disclaims any obligation to update any forward-looking statements.

Investor Contact:
LaVoie Health Science
Aurora Krause, 617-374-8800
Media Contact:
MacDougall Biomedical Communications
Chris Erdman, 781-235-3060

Source: Dicerna Pharmaceuticals, Inc.

News Provided by Acquire Media